"Tacrolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.
| Descriptor ID |
D016559
|
| MeSH Number(s) |
D02.540.505.810
|
| Concept/Terms |
Anhydrous Tacrolimus- Anhydrous Tacrolimus
- Tacrolimus, Anhydrous
- Tacrolimus Anhydrous
- Anhydrous, Tacrolimus
|
Below are MeSH descriptors whose meaning is more general than "Tacrolimus".
Below are MeSH descriptors whose meaning is more specific than "Tacrolimus".
This graph shows the total number of publications written about "Tacrolimus" by people in this website by year, and whether "Tacrolimus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 1 | 1 | 2 |
| 1996 | 3 | 1 | 4 |
| 1997 | 1 | 4 | 5 |
| 1998 | 1 | 1 | 2 |
| 1999 | 2 | 0 | 2 |
| 2000 | 5 | 2 | 7 |
| 2001 | 1 | 4 | 5 |
| 2002 | 0 | 1 | 1 |
| 2003 | 4 | 3 | 7 |
| 2004 | 1 | 5 | 6 |
| 2005 | 2 | 0 | 2 |
| 2006 | 4 | 5 | 9 |
| 2007 | 3 | 1 | 4 |
| 2008 | 0 | 5 | 5 |
| 2009 | 2 | 2 | 4 |
| 2010 | 3 | 5 | 8 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 2 | 3 |
| 2013 | 2 | 3 | 5 |
| 2014 | 3 | 3 | 6 |
| 2015 | 4 | 2 | 6 |
| 2016 | 1 | 6 | 7 |
| 2017 | 1 | 3 | 4 |
| 2018 | 2 | 4 | 6 |
| 2019 | 2 | 2 | 4 |
| 2020 | 5 | 1 | 6 |
| 2021 | 2 | 3 | 5 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tacrolimus" by people in Profiles.
-
Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplant Cell Ther. 2023 Dec; 29(12):770.e1-770.e6.
-
Brain a2d-1-Bound NMDA Receptors Drive Calcineurin Inhibitor-Induced Hypertension. Circ Res. 2023 09 15; 133(7):611-627.
-
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. N Engl J Med. 2023 Jun 22; 388(25):2338-2348.
-
External assessment and refinement of a population pharmacokinetic model to guide tacrolimus dosing in pediatric heart transplant. Pharmacotherapy. 2023 07; 43(7):650-658.
-
Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation. Transplant Cell Ther. 2022 10; 28(10):695.e1-695.e10.
-
Calcineurin Controls Hypothalamic NMDA Receptor Activity and Sympathetic Outflow. Circ Res. 2022 08 05; 131(4):345-360.
-
Mycophenolate Mofetil: A Friend or a Foe with Post-Transplantation Cyclophosphamide and Tacrolimus Prophylaxis in HLA-Matched Donors? Transplant Cell Ther. 2022 08; 28(8):500.e1-500.e10.
-
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol. 2022 02 01; 40(4):356-368.
-
Computational validation of ABCB1 gene polymorphism and its effect on tacrolimus dose concentration/levels in renal transplant individuals of South India. Comput Biol Med. 2021 12; 139:104971.
-
Practical Consideration for Drug Monitoring of Tacrolimus in Liver Transplantation Recipients with SARS-CoV-2 Infection. Liver Transpl. 2022 01; 28(1):127-130.